Skip to main content
SpringerLink
Log in

Analysis of T-Cell Receptor Variability in Tumour Infiltrating Lymphocytes

  • Conference paper
Lymphohaematopoietic Growth Factors in Cancer Therapy II

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 31 Accesses

Abstract

“Adoptive immunotherapy” is defined as the transfer to the patient of immunologically active agents. One method studied extensively in recent years is based on the in vivo infusion of cells displaying in vitro antitumour cytotoxic activity. This approach is most often combined with host system stimulation (“active immunotherapy”) aimed at the rejection of the tumour by, for example, infusions of IL-2, a pivotal mediator of the immune system. In animal models, the addition of in vitro IL-2-activated lymphocytes (the so-called Lymphokine Activated Killer cells) to the lymphokine infusions was found to be generally required to increase response rates and to improve the quality of tumour regression. The beneficial effects are to a great extent adoptive, as strongly suggested by the study of antitumour responses in immuno-depleted animals; the critical effectors of the antitumour response are the transfused cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ortaldo JR, Mason A and Overton R: Lymphokine- activated killer cells: Analysis of progenitors and effectors. J Exp Med 1986 (164):1193–1205

    Google Scholar 

  2. Phillips JH and Lanier LL: Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986 (164):814–825

    Google Scholar 

  3. Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F and Escudier B: Immunotherapy with lymphokine-activated Natural Killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma. J Biol Resp Mod 1990 (9):546–555

    Google Scholar 

  4. Farace F, Le Ridant AM, Escudier B, Hercend T and Triebel F: Studies on NK cell purification by negative selection in human peripheral blood. Biotherapy 1992 (in press)

    Google Scholar 

  5. Rosenberg SA: Immunotherapy of cancer using Interleukin 2: current status and future prospects. Immunol Today 1988 (9):58–62

    Google Scholar 

  6. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG and Rosenberg SA: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant lnterleukin-2: a pilot study. J Clin Oncol 1988 (6):839–853

    Google Scholar 

  7. Itoh K, Platsoucas CD and Balch CM: Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by Interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988 (168):1419–1441

    Google Scholar 

  8. Anichini A, Mazzocchi A, Fossati G and Parmiani G: Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol 1989 (142):3692–3701

    Google Scholar 

  9. Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR and Ergin MT: Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 1989 (169):1961–1976

    Google Scholar 

  10. Topalian SL, Solomon D and Rosenberg SA: Tumor- specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989 (142):3714–3725

    Google Scholar 

  11. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM and Rosenberg SA: Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989 (7):250–261

    Google Scholar 

  12. Meuer SC, Fitzgerald KA, Hussey RE, Hodgdon JC, Schlossman SF and Reinherz EL: Clonotypic structures involved in antigen-specific human T cell function. J Exp Med 1983 (157):705–719

    Google Scholar 

  13. Davis MM and Bjorkman PJ: T-cell antigen receptor genes and T-cell recognition. Nature 1988 (334):395–402

    Google Scholar 

  14. Roman-Roman S, Ferradini L, Azocar J, Genevee C, Hercend T and Triebel F: Studies on the human T cell receptor a/6 variable region genes. I. Identification of 7 additional Va subfamilies and 14 Jet gene segments. Eur J Immunol 1991 (21):927–933

    Google Scholar 

  15. Ferradini L, Roman-Roman S, Azocar J, Michalaki H, Triebel F and Hercend T: Studies on the human T cell receptor aß variable region genes. II. Identification of four additional VB subfamilies. Eur J Immunol 1991 (21):935–942

    CAS  Google Scholar 

  16. Leiden JM and Strominger JL: Generation of diversity of the 6 chain of the human T-lymphocyte receptor for antigen. Proc Natl Acad Sci USA 1986 (83):4456–4460

    Article  PubMed  CAS  Google Scholar 

  17. Genevee C, Diu A, Nierat M, Caignard A, Dietrich P- Y, Ferradini L, Roman-Roman S, Triebel F and Hercend T: An experimentally validated panel of subfamily-specific oligonucleotide primers (Va1- w29/Vß1-w24) for the study of human T-cell receptor V gene usage by polymerase chain reaction. Eur J Immunol 1992 (in press)

    Google Scholar 

  18. Broeren CPM, Verjans GM, Van Eden W, Kusters JG, Lenstra JA and Logtenberg T: Conserved nucleotide sequences at the 5’ end of T-cell receptor variable genes facilitate polymerase chain reaction amplification. Eur J Immunol 1991 (21):569–575

    Article  PubMed  CAS  Google Scholar 

  19. Frohman MA, Dush MK and Martin GR: Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene- specific oligonucleotide primer. Proc Natl Acad Sci USA 1988 (85):8998–9002

    Google Scholar 

  20. Ohara O, Dorit RL and Gilbert W: One-sided polymerase chain reaction: the amplification of cDNA. Proc Natl Acad Sci USA 1989 (86):5673–5677

    Google Scholar 

  21. Loh EY, Elliott JF, Cwirla S, Lanier LL and Davis MM: Polymerase chain reaction with single-sided specificity: analysis of T cell receptor 3 chain. Science 1989 (243):217–220

    Article  PubMed  CAS  Google Scholar 

  22. Ferradini L, Roman-Roman S, Azogui O, Praz F, Diu A, Hercend T and Triebel F: The use of the anchored polymerase chain reaction for the study of T-cell receptor variable regions by cDNA amplification, (manuscript submitted)

    Google Scholar 

  23. Kanagawa O: In vivo T cell tumor therapy with monoclonal antibody directed to the VB chain of T cell antigen receptor. J Exp Med 1989 (170):1513–1519

    Article  PubMed  CAS  Google Scholar 

  24. Nitta T, Oksenberg JR, Rao NA Steinman L: Predominant expression of T cell receptor Va7 in tumor-infiltrating lymphocytes of uveal melanoma. Science 1990 (249):672–674

    Article  PubMed  CAS  Google Scholar 

  25. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, Zamvil SS, McDevitt HO Steinman L: Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988 (54):263–273

    Article  PubMed  CAS  Google Scholar 

  26. Urban JL, Kumar V, Kono DH, Gomez C, Horvath SJ, Clayton J, Ando DG, Sercarz EE and Hood L: Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 1988 (54):577–592

    Article  PubMed  CAS  Google Scholar 

  27. Oksenberg JR, Stuart S, Begovich AB, Bell RB, Erlich HA, Steinman L and Bernard CCA: Limited heterogeneity of rearranged T-cell receptor Va transcripts in brains of multiple sclerosis patients. Nature 1990 (345):344–346

    Google Scholar 

  28. Poppema S, Bröcker EB, De Leij L, Terbrack D, Visscher T, Ter Haar A, Macher E, Thé TH and Sorg C: In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol 1983 (51):77–82

    PubMed  CAS  Google Scholar 

  29. Cardi G, Mastrangelo MJ and Berd D: Depletion of T- cells with the CD4+ CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Research 1989 (49):6562–6565

    Google Scholar 

  30. McGovern VJ: Spontaneous regression of malignant melanoma. In: Blaustein A (ed) Melanoma: Histological Diagnosis and Prognosis. Raven Press, New York 1982 pp 138–147

    Google Scholar 

  31. Anichini A, Fossati G and Parmiani G: Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma. Int J Cancer 1985 (35):683–689

    Google Scholar 

  32. Miescher S, Whiteside TL, Moretta L and Von Fliedner V: Clonal and frequency analysis of tumor- infiltrating T lymphocytes from human solid tumors. J Immunol 1987 (138):4004–4011

    Google Scholar 

  33. Mesler Muul L, Spiess PJ, Director EP and Rosenberg SA: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987 (138):989–995

    Google Scholar 

  34. Herin M, Lemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A, Devos R and Boon T: Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 1987 (39):390–397

    Google Scholar 

  35. Wölfel T, Klehmann E, Müller C, Schütt KH, Meyer Zum Büschenfelde KH and Knuth A: Lysis of human melanoma cells by autologous cytolytic T cell clones. J Exp Med 1989 (170):797–810

    Google Scholar 

  36. Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE and Mukherji B: Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 1990 (145):2359–2364

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire d’Hémato-Immunologie, INSERM U333, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France

    Frédéric Triebel

Authors
  1. Frédéric Triebel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin I, Klinikum der Albert-Ludwigs-Universität, Hugstetter Straße 55, 7500, Freiburg, Federal Republic of Germany

    Roland Mertelsmann

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Triebel, F. (1992). Analysis of T-Cell Receptor Variability in Tumour Infiltrating Lymphocytes. In: Mertelsmann, R. (eds) Lymphohaematopoietic Growth Factors in Cancer Therapy II. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77801-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77801-8_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77803-2

  • Online ISBN: 978-3-642-77801-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation